Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patients
Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, reducing mortality and cardiovascular risks. The SURPASS-CVOT trial revealed Mounjaro's superiority over Trulicity, showing improvements in A1C levels, weight loss, and renal function. These findings support Mounjaro as a potential front-line therapy, with Lilly planning to submit the results to global regulatory authorities.
Agencies Lilly said that it will submit the results to the global regulatory authorities by the end of this year. Pharma major Eli Lilly today said that it's weight loss drug Mounjaro has helped in reducing cardiovascular risks in patients with Type 2 diabetes and heart disease. According to the results of the trial which included over 13,000 patients across 30 countries, including India, 16 % reduction in all-cause mortality was seen, 8% lower risk of heart attack, stroke, or cardiovascular death, reinforcing its potential as a breakthrough therapy for Indians living with type 2 diabetes and heart disease.
'Lilly's Mounjaro (tirzepatide) has shown superior cardiovascular protection over Trulicity in the landmark SURPASS-CVOT global trial,' it said in a statement.The trial also demonstrated significant improvements in A1C (-1.73%) and weight loss (-11.43 kg) for Mounjaro. A1C is a biomarker for Type 2 diabetes. Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed a definitive cardiovascular benefit in the REWIND study.
'In SURPASS-CVOT, Mounjaro achieved the primary objective by demonstrating a non-inferior rate of major adverse cardiovascular events (MACE- 3), including cardiovascular death, heart attack or stroke vs. Trulicity. In addition, Mounjaro showed improvements on key measures of A1C, weight, renal function and all-cause mortality,' it further said.The trial lasted more than four and a half years and is the largest and longest study of tirzepatide to date.'Cardiovascular disease continues to be the leading cause of death among individuals with type 2 diabetes,' said Winselow Tucker, President and General Manager, Eli Lilly and Company (India). 'The SURPASS-CVOT trials highlight that Mounjaro maintains the cardioprotective effects seen with Trulicity, a GLP-1 receptor agonist, while offering additional advantages such as a slower eGFR decline and a lower mortality rate. These results further support Mounjaro's potential as a front-line therapy for people managing both type 2 diabetes and cardiovascular conditions."Doctors say the results of the study will help the company secure label expansions to reduce the risk of cardiovascular issues.The heart-helping benefits of GLP-1 drugs have been well established. Earlier in 2020, lilly's rival Novo Nordisk's Ozempic was approved to reduce cardiovascular risks in Type 2 diabetes patients by the FDA.Lilly said that it will submit the results to the global regulatory authorities by the end of this year. In September, the company will present detailed data from the trial at the European Association for the Study of Diabetes annual meeting in Vienna.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Pharma Inc gears up for Day 1 launch of obesity drug in March 2026
As the global demand for next-generation diabetes and weight-loss therapies surge, Indian pharmaceutical companies are stepping up preparations to roll out generic versions of semaglutide—a blockbuster GLP-1 receptor agonist—once patent expires around March 2026. The generic launches will be significant, as the prices for the Indian consumer are expected to come down significantly from the current ₹17,000-26000 (monthly), thereby expanding the patient coverage. Dr. Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, and others are ramping up peptide manufacturing, forming device partnerships, and aligning regulatory strategies to capture a share of the global GLP-1 market, estimated to cross $150 billion by decade's end. Hyderabad-based DRL is planning Day 1 launches in India and Brazil, part of a 2026 global rollout across 87 countries. 'The semaglutide launch is very important to us,' said CEO Erez Israeli. The company aims to price its product below Novo Nordisk's current ₹17,000 monthly offering. DRL is also working on 26 GLP-1 therapies, backed by a ₹2,700 crore FY26 capex plan to scale peptide and biosimilar production. Cipla is targeting first-wave launches through a mix of in-house and partner filings. 'We see GLP-1 as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, MD and global CEO at the post earnings call. The company is building parts of its GLP-1 supply chain internally while leveraging partnerships to ensure scalability. Cipla is also crafting an affordable strategy for India's price-sensitive market, betting that post-patent price erosion will be offset by volume growth. Mankind Pharma aims to launch both oral and injectable semaglutide generics and is advancing MKP10241, a novel oral obesity drug in Phase 2 trials in Australia. Sun Pharma, meanwhile, is progressing its investigational GLP-1 molecule Utreglutide, targeted for launch in four to five years. It has secured Phase III approval for semaglutide trials in India, even as it reports negligible impact of GLP-1 drugs on its existing diabetes portfolio. The race for a piece of India's ₹628 crore anti-obesity market, however, comes at a time when the Indian courts and drug regulator body are looking to monitor the unregulated use of weight loss drugs. According to sources, the Central Drug Standards Control Organisation (CDSCO) has initiated work to form a panel after the Delhi High Court in July 2025 asked it to consult experts and relevant stakeholders to look into concerns arising out of approval for drug combinations being sold in the market for weight loss. The directive came in response to a public interest litigation filed by fitness entrepreneur Jitendra Chouksey, who had raised concerns about the marketing approval of drugs such as semaglutide, tirzepatide and liraglutide for weight management, despite limited safety data and the absence of India-specific clinical trials. While disposing of the petition, the court asked the drug regulator to respond to the petitioner within three months. At present, India has two officially available semaglutide brands: Rybelsus (oral) and Wegovy (injectable), both from Danish major Novo Nordisk. Rybelsus is approved for treating Type 2 diabetes, while Wegovy was launched in June 2025 for weight management. US-based Eli Lilly's tirzepatide drug, Mounjaro, is also available in India for obesity management. Analysts say the semaglutide opportunity is also fuelling India's peptide manufacturing ecosystem. 'Formulation is no longer enough—companies need full-stack execution,' said Nirali Shah, Pharma Analyst at Ashika Group, pointing to DRL, Cipla, and Sun Pharma's early moves to secure pen delivery partnerships. Contract development and manufacturing organisations (CDMOs) like Anthem Biosciences and Syngene are positioning themselves to capture a larger share of the growing peptide segment. Device manufacturers, too, are scaling up to meet rising demand for injection pens. India's peptide CDMO market, currently valued at $80 million, is growing at a CAGR of 14 per cent and could become a global supplier base for GLP-1 drugs, said Nilaya Varma, CEO of Primus Partners.
Indian Express
4 hours ago
- Indian Express
Chef Sanjyot Keer claims his ‘liquid laddoo' is the perfect cure for cold and cough — we find out if it's true
Since time immemorial, our first line of defence against cold, cough, headache, sore throat, and everything in between has been our grandma's kitchen. Being Indians, it goes beyond saying that Chef Sanjyot Keer's new 'liquid laddoo' recipe took us down the memory lane and filled our hearts with nostalgia. 'Punjabi gharo mein, hamari nani-dadi yeh delicious recipe banati hai which we call besan ka sheera, aisa lagta hai jaise kisi ne ek besan ka ladoo pighla ke cup mein daal diya ho, it's that delicious and comforting,' he captioned his latest Instagram post. Having said that, can this 'liquid laddoo' rationally serve as a miracle cure to your cough and cold this rainy season or might just end up as another viral comfort drink? spoke to Dr. Yashawant Kumar – Founder and CEO, Benefic Nutrition and found out. Almonds: Packed with healthy fats, proteins, and vitamin E, almonds add nutritional value and mild nourishment. They are a good source of energy but not a direct decongestant. Ghee: Ghee can help soothe and lubricate irritated throat. It can calm mucosal membranes and offer symptomatic relief. Besan: Besan is not directly therapeutic, nevertheless it has Vitamin B₁ and antioxidants, which can help with fatigue during sickness. Milk: Milk can comfort and calm the body. When taken along with spices and ghee, it can help clear mucus and fall asleep better. Turmeric Powder: Turmeric is proven to have antiviral, antiseptic, and antibacterial properties. The curcumin in haldi has anti-inflammatory properties and can help reduce inflammation. Black Pepper Powder: When black pepper is taken along with turmeric, it can help with the absorption of curcumin by the body. Black pepper also has antibacterial properties and can help relax sore throat. Cardamom Powder: Cardamom has a long history of serving as an ingredient in various Ayurvedic medicines for respiratory discomfort. It can help with digestion and congestion. Ginger Powder: Ginger is known to have anti-inflammatory and antimicrobial properties. It can soothe throat inflammation and suppress cough. Kesar: There is no evidence of kesar helping to relieve cough. However, it might offer a warm thermogenic effect. Jaggery Powder: The sweet taste of jaggery helps in improving palatability during illness. It may also help soothe the throat and clear mucus. According to Dr Kumar, turmeric, black pepper, and ginger can help reduce inflammation and congestion. 'Almonds and besan can provide much needed nutrients to the body and can relieve fatigue. They also aid digestion and improve energy levels during illness. Milk and ghee can help relax and fall asleep better,' he explained. However, he warned that this remedy is not proven clinically and is not a scientific cure. The ingredients in this recipe only offer temporary symptomatic relief and comfort. 'The 'liquid laddoo' recipe by Chef Sanjyot Keer is not a magic bullet, but it's not a false buzz either. Clearly, it's a clean home remedy with its ingredients rooted in Indian Ayurveda,' said Dr Kumar, adding that the drink indeed has the potential of providing a soothing and calming experience to the body during cold and cough. DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
Pharma Inc gear up for Day 1 launch of obesity drug in March 2026
As the global demand for next-generation diabetes and weight-loss therapies surge, Indian pharmaceutical companies are stepping up preparations to roll out generic versions of semaglutide—a blockbuster GLP-1 receptor agonist—once patent expires around March 2026. The generic launches will be significant, as the prices for the Indian consumer are expected to come down significantly from the current ₹17,000-26000 (monthly), thereby expanding the patient coverage. Dr. Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, and others are ramping up peptide manufacturing, forming device partnerships, and aligning regulatory strategies to capture a share of the global GLP-1 market, estimated to cross $150 billion by decade's end. Hyderabad-based DRL is planning Day 1 launches in India and Brazil, part of a 2026 global rollout across 87 countries. 'The semaglutide launch is very important to us,' said CEO Erez Israeli. The company aims to price its product below Novo Nordisk's current ₹17,000 monthly offering. DRL is also working on 26 GLP-1 therapies, backed by a ₹2,700 crore FY26 capex plan to scale peptide and biosimilar production. Cipla is targeting first-wave launches through a mix of in-house and partner filings. 'We see GLP-1 as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, MD and global CEO at the post earnings call. The company is building parts of its GLP-1 supply chain internally while leveraging partnerships to ensure scalability. Cipla is also crafting an affordable strategy for India's price-sensitive market, betting that post-patent price erosion will be offset by volume growth. Mankind Pharma aims to launch both oral and injectable semaglutide generics and is advancing MKP10241, a novel oral obesity drug in Phase 2 trials in Australia. Sun Pharma, meanwhile, is progressing its investigational GLP-1 molecule Utreglutide, targeted for launch in four to five years. It has secured Phase III approval for semaglutide trials in India, even as it reports negligible impact of GLP-1 drugs on its existing diabetes portfolio. The race for a piece of India's ₹628 crore anti-obesity market, however, comes at a time when the Indian courts and drug regulator body are looking to monitor the unregulated use of weight loss drugs. According to sources, the Central Drug Standards Control Organisation (CDSCO) has initiated work to form a panel after the Delhi High Court in July 2025 asked it to consult experts and relevant stakeholders to look into concerns arising out of approval for drug combinations being sold in the market for weight loss. The directive came in response to a public interest litigation filed by fitness entrepreneur Jitendra Chouksey, who had raised concerns about the marketing approval of drugs such as semaglutide, tirzepatide and liraglutide for weight management, despite limited safety data and the absence of India-specific clinical trials. While disposing of the petition, the court asked the drug regulator to respond to the petitioner within three months. At present, India has two officially available semaglutide brands: Rybelsus (oral) and Wegovy (injectable), both from Danish major Novo Nordisk. Rybelsus is approved for treating Type 2 diabetes, while Wegovy was launched in June 2025 for weight management. US-based Eli Lilly's tirzepatide drug, Mounjaro, is also available in India for obesity management. Analysts say the semaglutide opportunity is also fuelling India's peptide manufacturing ecosystem. 'Formulation is no longer enough—companies need full-stack execution,' said Nirali Shah, Pharma Analyst at Ashika Group, pointing to DRL, Cipla, and Sun Pharma's early moves to secure pen delivery partnerships. Contract development and manufacturing organisations (CDMOs) like Anthem Biosciences and Syngene are positioning themselves to capture a larger share of the growing peptide segment. Device manufacturers, too, are scaling up to meet rising demand for injection pens. India's peptide CDMO market, currently valued at $80 million, is growing at a CAGR of 14 per cent and could become a global supplier base for GLP-1 drugs, said Nilaya Varma, CEO of Primus Partners.
